Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study

References

• The Tobacco Atlas. World Health Organization. 2002. Available at: http://www.who.int/tobacco/en/atlas11.pdf [Last accessed 9 June 2010]
   Google Scholar
• Fiore MC, McCarthy DE, Jackson TC, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. Prev Med 2004;38:412-20
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Cigarette smoking among adults–United States, 2000. MMWR 2002;51:642-5
   PubMedGoogle Scholar
• Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38
   PubMed Web of Science ®Google Scholar
• Fiore M, Jaén C, Baker T, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2008
   Google Scholar
• U.S. Public Health Service. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008;53:1217-22
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221-9
   PubMed Web of Science ®Google Scholar
• Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009;31:177-89
   PubMed Web of Science ®Google Scholar
• Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009;14:384-92
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63
   PubMed Web of Science ®Google Scholar
• Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56
   PubMed Web of Science ®Google Scholar
• Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008;24:1931-41
   PubMed Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8
   PubMed Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55
   PubMed Web of Science ®Google Scholar
• Tashkin D, Rennard S, Hays J, et al. Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized trial. Chest 2010;TBA
   Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007;CD006103
   PubMed Web of Science ®Google Scholar
• Grootendorst DC, Jager KJ, Dekker FW. Observational studies are complementary to randomized controlled trials. Nephron Clin Pract 2010;114:c173-7
   PubMedGoogle Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar
• Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008;1:211-17
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Haidich A-B, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286:821-30
   PubMed Web of Science ®Google Scholar
• Ramon JM, Bruguera E. Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Public Health 2009;6:1530-8
   PubMed Web of Science ®Google Scholar
• Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103:146-54
   PubMed Web of Science ®Google Scholar
• Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805
   PubMed Web of Science ®Google Scholar
• Halperin AC, McAfee TA, Jack LM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat 2009;36:428-34
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics (Champix). Pfizer Ltd. 2009. Available at: http://www.medicines.org.uk/emc/medicine/19045/SPC/CHAMPIX++0.5+mg+film-coated+tablets%3B+CHAMPIX++1+mg+film-coated+tablets/ [Last accessed 9 June 2010]
   Google Scholar
• Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-7
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71
   PubMed Web of Science ®Google Scholar
• Shipton D, Tappin DM, Vadiveloo T, et al. Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional study. BMJ 2009;339:b4347
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Cherry NM, Mc LNR, et al. Cotinine levels and self-reported smoking status in patients attending a bronchoscopy clinic. Biomarkers 2003;8:218-28
   PubMed Web of Science ®Google Scholar
• Mak YW, Loke AY, Lam TH, et al. Validity of self-reports and reliability of spousal proxy reports on the smoking behavior of Chinese parents with young children. Addict Behav 2005;30:841-5
   PubMed Web of Science ®Google Scholar
• Studts JL, Ghate SR, Gill JL, et al. Validity of self-reported smoking status among participants in a lung cancer screening trial. Cancer Epidemiol Biomarkers Prev 2006;15:1825-8
   PubMed Web of Science ®Google Scholar
• Becoña E, Míguez M. Concordance of self-reported abstinence and measurement of expired air carbon monoxide in a self-help smoking cessation treatment. Psychol Rep 2006;99:125-30
   PubMed Web of Science ®Google Scholar
• Barrueco M, Jiménez Ruiz C, Ruiz C, et al. [Veracity of smokers' reports of abstinence at smoking cessation clinics]. Arch Bronconeumol 2005;41:135-40
   PubMed Web of Science ®Google Scholar
• McDonald SD, Perkins SL, Walker MC. Correlation between self-reported smoking status and serum cotinine during pregnancy. Addict Behav 2005;30:853-7
   PubMed Web of Science ®Google Scholar
• Glynn SM, Gruder CL, Jegerski JA. Effects of biochemical validation of self-reported cigarette smoking on treatment success and on misreporting abstinence. Health Psychol 1986;5:125-36
   PubMed Web of Science ®Google Scholar
• Blak BT, Wilson K, Metcalfe M, et al. Evaluation of varenicline as an aid to smoking cessation in UK general practice - a THIN database study. Curr Med Res Opin 2010;26:861-70
   PubMed Web of Science ®Google Scholar
• Hays JT, Leischow SJ, Lawrence D, et al. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res 2010;12:574-81
   PubMed Web of Science ®Google Scholar
• Rovina N, Nikoloutsou I, Dima E, et al. Smoking cessation treatment in a real-life setting: the Greek experience. Ther Adv Respir Dis 2007;1:93-104
   PubMedGoogle Scholar
• Rebelo K. Varenicline effective for highly nicotine-dependent smokers with COPD. Presented at Annual Meeting of the American College of Chest Physicians 2009. San Diego, CA
   Google Scholar